O	0	8	Clinical
O	9	19	usefulness
O	20	22	of
B-intervention	23	31	eribulin
O	32	34	as
O	35	40	first
O	40	41	-
O	42	44	or
O	45	51	second
O	51	52	-
O	52	56	line
O	57	69	chemotherapy
O	70	73	for
O	74	83	recurrent
O	84	88	HER2
O	88	89	-
O	89	97	negative
O	98	104	breast
O	105	111	cancer
O	111	112	:
O	113	114	a
O	115	125	randomized
O	126	131	phase
O	132	134	II
O	135	140	study
O	141	142	(
O	142	147	JBCRG
O	147	148	-
O	148	150	19
O	150	151	)
O	151	152	.

O	153	166	Anthracycline
O	167	168	(
O	168	169	A
O	169	170	)
O	171	173	or
O	174	180	taxane
O	181	182	T
O	182	183	-
O	183	188	based
O	189	197	regimens
O	198	201	are
O	202	205	the
O	206	214	standard
O	215	220	early
O	220	221	-
O	221	225	line
O	226	238	chemotherapy
O	239	242	for
O	243	253	metastatic
O	254	260	breast
O	261	267	cancer
O	268	269	(
O	269	271	BC
O	271	272	)
O	272	273	.

O	274	275	A
O	276	284	previous
O	285	290	study
O	291	294	has
O	295	300	shown
O	301	302	a
O	303	311	survival
O	312	319	benefit
O	320	322	of
O	323	331	eribulin
O	332	334	in
O	335	342	heavily
O	343	353	pretreated
O	354	362	advanced
O	362	363	/
O	363	372	recurrent
O	373	375	BC
O	376	384	patients
O	384	385	.

O	386	389	The
O	390	397	present
O	398	403	study
O	404	409	aimed
O	410	412	to
O	413	420	compare
O	421	424	the
O	425	432	benefit
O	433	435	of
O	436	444	eribulin
O	445	449	with
O	450	459	treatment
O	460	462	of
O	463	472	physician
O	472	473	'
O	473	474	s
O	475	481	choice
O	482	483	(
O	483	486	TPC
O	486	487	)
O	488	490	as
O	491	496	first
O	496	497	-
O	498	500	or
O	501	507	second
O	507	508	-
O	508	512	line
O	513	525	chemotherapy
O	526	529	for
O	530	539	recurrent
O	540	544	HER2
O	544	545	-
O	545	553	negative
O	554	556	BC
O	556	557	.

B-eligibility	558	566	Patients
I-eligibility	567	571	with
I-eligibility	572	581	recurrent
I-eligibility	582	586	HER2
I-eligibility	586	587	-
I-eligibility	587	595	negative
I-eligibility	596	598	BC
I-eligibility	599	609	previously
I-eligibility	610	619	receiving
I-eligibility	620	633	anthracycline
I-eligibility	634	637	and
I-eligibility	638	644	taxane
I-eligibility	645	647	AT
I-eligibility	647	648	-
I-eligibility	648	653	based
I-eligibility	654	666	chemotherapy
I-eligibility	667	669	in
I-eligibility	670	673	the
I-eligibility	674	682	adjuvant
I-eligibility	683	685	or
I-eligibility	686	691	first
I-eligibility	691	692	-
I-eligibility	692	696	line
I-eligibility	697	704	setting
O	705	709	were
O	710	718	eligible
O	719	722	for
O	723	727	this
O	728	732	open
O	732	733	-
O	733	738	label
O	738	739	,
O	740	750	randomized
O	750	751	,
O	752	760	parallel
O	760	761	-
O	761	766	group
O	767	772	study
O	772	773	.

O	774	782	Patients
O	783	787	were
O	788	798	randomized
O	799	800	1
O	800	801	:
O	801	802	1
O	803	805	by
O	806	809	the
O	810	822	minimization
O	823	829	method
O	830	832	to
O	833	840	receive
O	841	847	either
O	848	856	eribulin
O	857	858	(
O	858	859	1
O	859	860	.
O	860	861	4
O	862	864	mg
O	864	865	/
O	865	867	m2
O	868	870	on
O	871	874	day
O	875	878	one
O	879	882	and
O	883	888	eight
O	889	891	of
O	892	896	each
O	897	899	21
O	899	900	-
O	900	903	day
O	904	909	cycle
O	909	910	)
O	911	913	or
B-control	914	917	TPC
O	918	919	(
O	919	929	paclitaxel
O	929	930	,
O	931	940	docetaxel
O	940	941	,
O	942	945	nab
O	945	946	-
O	946	956	paclitaxel
O	957	959	or
O	960	971	vinorelbine
O	971	972	)
O	973	978	until
O	979	986	disease
O	987	998	progression
O	999	1001	or
O	1002	1014	unacceptable
O	1015	1023	toxicity
O	1023	1024	.

O	1025	1028	The
O	1029	1036	primary
O	1037	1045	endpoint
O	1046	1049	was
B-outcome-Measure	1050	1061	progression
I-outcome-Measure	1061	1062	-
I-outcome-Measure	1062	1066	free
I-outcome-Measure	1067	1075	survival
I-outcome-Measure	1076	1077	(
I-outcome-Measure	1077	1080	PFS
I-outcome-Measure	1080	1081	)
O	1081	1082	.

O	1083	1092	Secondary
O	1093	1102	endpoints
O	1103	1111	included
B-outcome-Measure	1112	1116	time
I-outcome-Measure	1117	1119	to
I-outcome-Measure	1120	1129	treatment
I-outcome-Measure	1130	1137	failure
I-outcome-Measure	1138	1139	(
I-outcome-Measure	1139	1142	TTF
I-outcome-Measure	1142	1143	)
O	1143	1144	,
B-outcome-Measure	1145	1152	overall
I-outcome-Measure	1153	1161	response
I-outcome-Measure	1162	1166	rate
I-outcome-Measure	1167	1168	(
I-outcome-Measure	1168	1171	ORR
I-outcome-Measure	1171	1172	)
O	1172	1173	,
B-outcome-Measure	1174	1182	duration
I-outcome-Measure	1183	1185	of
I-outcome-Measure	1186	1194	response
O	1194	1195	,
O	1196	1199	and
B-outcome-Measure	1200	1206	safety
O	1207	1208	(
O	1208	1221	UMIN000009886
O	1221	1222	)
O	1222	1223	.

O	1224	1231	Between
O	1232	1235	May
O	1236	1240	2013
O	1241	1244	and
O	1245	1252	January
O	1253	1257	2017
O	1257	1258	,
B-total-participants	1259	1261	58
O	1262	1270	patients
O	1271	1275	were
O	1276	1286	randomized
O	1286	1287	,
B-total-participants	1288	1290	57
O	1291	1293	of
O	1294	1298	whom
O	1299	1300	(
B-intervention-participants	1300	1302	26
O	1303	1311	eribulin
O	1312	1315	and
B-control-participants	1316	1318	31
O	1319	1322	TPC
O	1322	1323	)
O	1324	1328	were
O	1329	1337	analyzed
O	1338	1341	for
O	1342	1350	efficacy
O	1350	1351	.

O	1352	1355	The
B-outcome	1356	1362	median
I-outcome	1363	1366	PFS
O	1367	1370	was
B-iv-cont-median	1371	1372	6
I-iv-cont-median	1372	1373	.
I-iv-cont-median	1373	1374	6
I-iv-cont-median	1375	1381	months
O	1382	1386	with
O	1387	1395	eribulin
O	1396	1402	versus
B-cv-cont-median	1403	1404	4
I-cv-cont-median	1404	1405	.
I-cv-cont-median	1405	1406	2
I-cv-cont-median	1407	1413	months
O	1414	1418	with
O	1419	1422	TPC
O	1423	1424	(
O	1424	1430	hazard
O	1431	1436	ratio
O	1436	1437	:
O	1438	1439	0
O	1439	1440	.
O	1440	1442	72
O	1443	1444	[
O	1444	1446	95
O	1446	1447	%
O	1448	1458	confidence
O	1459	1467	interval
O	1468	1469	(
O	1469	1471	CI
O	1471	1472	)
O	1472	1473	,
O	1474	1475	0
O	1475	1476	.
O	1476	1478	40
O	1478	1479	-
O	1479	1480	1
O	1480	1481	.
O	1481	1483	30
O	1483	1484	]
O	1484	1485	,
O	1486	1487	p
O	1488	1489	=
O	1490	1491	0
O	1491	1492	.
O	1492	1495	276
O	1495	1496	)
O	1496	1497	.

B-outcome	1498	1504	Median
I-outcome	1505	1508	TTF
O	1509	1512	was
B-iv-cont-median	1513	1514	6
I-iv-cont-median	1514	1515	.
I-iv-cont-median	1515	1516	0
I-iv-cont-median	1517	1523	months
O	1524	1528	with
O	1529	1537	eribulin
O	1538	1544	versus
B-cv-cont-median	1545	1546	3
I-cv-cont-median	1546	1547	.
I-cv-cont-median	1547	1548	6
I-cv-cont-median	1549	1555	months
O	1556	1560	with
O	1561	1564	TPC
O	1565	1566	(
O	1566	1572	hazard
O	1573	1578	ratio
O	1578	1579	:
O	1580	1581	0
O	1581	1582	.
O	1582	1584	66
O	1585	1586	[
O	1586	1588	95
O	1588	1589	%
O	1590	1592	CI
O	1592	1593	,
O	1594	1595	0
O	1595	1596	.
O	1596	1598	39
O	1598	1599	-
O	1599	1600	1
O	1600	1601	.
O	1601	1603	14
O	1603	1604	]
O	1604	1605	,
O	1606	1607	p
O	1608	1609	=
O	1610	1611	0
O	1611	1612	.
O	1612	1615	136
O	1615	1616	)
O	1616	1617	.

O	1618	1623	Other
O	1624	1633	endpoints
O	1634	1638	were
O	1639	1643	also
O	1644	1651	similar
O	1652	1659	between
O	1660	1666	groups
O	1666	1667	.

O	1668	1671	The
O	1672	1676	most
O	1677	1683	common
B-outcome	1684	1689	grade
I-outcome	1690	1691	â‰¥
I-outcome	1692	1693	3
I-outcome	1694	1701	adverse
I-outcome	1702	1707	event
O	1708	1711	was
B-outcome	1712	1723	neutropenia
O	1724	1725	(
B-iv-bin-percent	1725	1727	22
I-iv-bin-percent	1727	1728	.
I-iv-bin-percent	1728	1729	2
I-iv-bin-percent	1729	1730	%
O	1731	1735	with
O	1736	1744	eribulin
O	1745	1751	versus
B-cv-bin-percent	1752	1754	16
I-cv-bin-percent	1754	1755	.
I-cv-bin-percent	1755	1756	1
I-cv-bin-percent	1756	1757	%
O	1758	1762	with
O	1763	1766	TPC
O	1766	1767	)
O	1767	1768	.

O	1769	1777	Eribulin
O	1778	1784	seemed
O	1785	1787	to
O	1788	1795	improve
O	1796	1799	PFS
O	1800	1802	or
O	1803	1806	TTF
O	1807	1815	compared
O	1816	1820	with
O	1821	1824	TPC
O	1825	1832	without
O	1833	1844	statistical
O	1845	1857	significance
O	1857	1858	.

O	1859	1866	Further
O	1867	1877	validation
O	1878	1885	studies
O	1886	1889	are
O	1890	1896	needed
O	1896	1897	.
